AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
Business Wire•23/10/2026•17:00 ET
0
Key Highlights
- ➤AN2 grants options for 10,565 shares and 5,283 restricted stock units
- ➤Options carry a $3.37 exercise price, matching October 19 closing price
- ➤Two newly hired employees receive Nasdaq Rule 5635(c)(4) inducement awards
- ➤AN2 expects three Phase 2 studies active in 2026
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to two newly-hired employees.
Get started
Create a free account to read the full story.